Clinical significance of APRI and FIB4 in schistosomiasis patients with liver fibrosis
LEI Jianzhu1, ZU Deling2, JING Qizhi2
1.Department of Laboratory, Longyou County People’s Hospital, Quzhou 324400,China; 2.Department of Cardiology, Quzhou People’s Hospital, Quzhou 324000, China
LEI Jianzhu,ZU Deling,JING Qizhi. Clinical significance of APRI and FIB4 in schistosomiasis patients with liver fibrosis[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2022, 52(8): 663-666.
Abstract：Objective: To investigate the characteristics and clinical significance of aspartate aminotransferase to platelet ratio index (APRI) and fibrosis index based on the four factors (FIB4) in schistosomiasis patients with liver fibrosis. Methods: A total of 284 schistosomiasis patients with liver fibrosis in Longyou County People’s Hospital and Quzhou People’s Hospital from January 2019 to June 2021 were selected as the observation group, and 410 healthy subjects as the control group. At the same time, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBiL), platelet count (PLT) were tested, and APRI and FIB4 were calculated. Both groups were examined by B-type ultrasound to test the degree of liver fibrosis. Results: There was evidence to suggest that AST [(61.68±20.25)U/L], ALT [(38.50±13.86)U/L], TBiL [(38.58±18.41)μmol/L],APRI (2.67±1.15), FIB4 (8.51±0.71) in the observation group was respectively higher than those in the control group (P<0.001), with AST [(27.15±6.43)U/L], ALT [(21.21±10.16)U/L], TBiL [(11.23±5.01)μmol/L], APRI (0.49±0.16), FIB4 (0.67±0.03), showing significant difference. The PLT of the observation group was [(64.87±34.49)×109/L], lower than that of the control group [(147.92±48.93)×109/L] (P<0.001). The APRI values of hepatic fibrosis grade I subgroup and hepatic fibrosis grade II subgroup in the observation group were (1.81±0.54), (4.40±2.15) and FIB4 values were (5.38±2.34), (14.75±6.68), respectively (P<0.001). Evidence showed that there was positive correlation between APRI and FIB4 (r=0.757, P<0.001). Conclusion: Combined application of APRI and FIB4 in schistosomiasis patients with liver fibrosis can reflect the status of schistosomiasis liver fibrosis, which is of clinical value.
